In advanced HCC patients receiving first-line immunotherapy, metformin use has been associated with a trend toward worse clinical outcomes, although this did not reach statistical significance [ 229 ].
1
—
—
In advanced HCC patients receiving first-line immunotherapy, metformin use has been associated with a trend toward worse clinical outcomes, although this did not reach statistical significance [ 229 ].